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Abstract: Recent studies demonstrated that besides placenta and malignant trophoblastic tumors, hCG and especially its
β -subunit is secreted by a varieties of tumors of different origin. The aim of the present investigation was to determine the
expression pattern of human chorionic gonadotropin gene in ovarian cancer tissue. The study included 8 patients with epithelial
ovarian carcinoma. The expression and distribution of hCGβ  mRNA was assessed by in situ RT-PCR method. The
semi-quantitative assessment was performed using computer image analysis. Transformation of the images into the pseudo-
colour scale showed a clear difference in fluorescence intensity among individual cancer cells. The intensity of ISRT-PCR
products corresponding with expression level of hCGβ  demonstrated that its production by individual cancer cells is different.
In all studied specimens of the ovarian carcinoma tissue, cancer cells characterized by the presence of active hCGβ  gene were
found, whereas noncancerous tissue demonstrated lack of the gene expression. Thus, the study clearly shows that the expression
of hCGβ  is the feature of ovarian cancer tissue.
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Introduction
Human chorionic gonadotropin (hCG) is a sialoglyco-
protein hormone composed of two noncovalently linked
subunits - α  (hCGα ) and β  (hCGβ ) [24]. Physiologi-
cally, hCG is produced by syncytiotrophoblastic cells of
the placenta and secreted into blood, being present in
urine of pregnant women and patients with trophoblastic
diseases [3, 4]. The production of hCG, especially its
β -subunit by patients with nontrophoblastic cancers has
been reported by many authors and immunoreactive
hCG/hCGβ  has been detected in the blood of patients
with a variety of tumors of different origin [3, 5, 8, 9, 11,
16, 20, 23, 25]. The presence of hCG in any of its forms
is regarded as an in vivo phenotypic characteristic of
human cancer cells [16].
The role of hCG in tumorogenesis is unknown but
recent reports suggest that hCGβ  can stimulate growth
of cancer cells or inhibit the apoptosis and the elevated
serum level of hCGβ  correlates with higher aggressive-
ness of cancer and its resistance to the therapy [7, 15].
Intact hCG appears to be the main form of hCG immu-
noreactivity, whereas the expression of the free β  sub-
unit of hCGβ  has been associated with metastatic
phenotype of cancer cells, but the biological mechan-
isms behind this association remains unclear [8, 16,
23]. Although the serum immunoreactivity of hCG
and hCGβ  has been observed in patients with gyneco-
logical malignancies, there is almost no data of human
chorionic gonadotropin expression in gynecological
cancer tissue [12]. 
The aim of the present study was to analyze express-
ion of human chorionic gonadotropin gene in epithelial
ovarian cancer tissue. 
Materials and methods 
Tissue samples. Surgical specimens of cancer tissue were obtained
from 8 patients with epithelial ovarian carcinoma (median age 55 yrs,
range 40-69 yrs), treated by surgery at the Department of Gyneco-
logic Oncology, Poznan ´ University of Medical Sciences in 2003. In
all patients, histological confirmation of the cancer, including tumor
grading, was obtained and the staging was performed according to
the International Federation of Gynecology and Obstetric (FIGO).
Histology groups were as follows: ovarian cancer of serous type (5
cases, tumor grading G1 - 1, G2 - 2, G3 - 2; FIGO IA - 1, IC - 1, IIC
- 1, III - 2, IV - 1), ovarian cancer of mucinous type (1 case, tumor
grading not determined, FIGO III), clear cell type (1 case, tumor
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The control samples obtained from the same patients consisted of
surgically removed tissue which did not reveal any pathological
changes after macroscopic and histopathological examinations: en-
dometrium (2 samples) and the uterine cervix (1 sample) were
collected. Two samples of placentas from term delivery served as a
positive control. 
The samples, collected at the operation were immediately fixed
in 4% buffered formaldehyde, processed, embedded in paraffin and
stored at 4˚C. The patients were not treated by chemotherapy or
radiotherapy prior to operation. 
RT PCR in situ. In order to detect the hCGβ  mRNA, the paraffin
sections were prepared according to the procedure described by
Bagasra and coworkers [2, 24]. Reverse transcripton in situ was
performed using Expand Reverse Transcriptase (Roche Molecular
Biochemicals, Mannheim, Germany) with the primer specific for the
hCGβ  gene (reverse primer: 5’-GAGAAGCCTTTATTGTG-3’,
complementary to nucleotides 51595-51611, PubMed, AC:
NG000019). A 210 bp fragment of cDNA of the hCGβ  gene tran-
script was amplified by in situ PCR, using the following primers:
sense 5’-GCAGGGGACGCACCAAGGA-3’ (nucleotides 50499-
50518 according to DNA sequence, PubMed, AC: NG000019) and
antisense 5’- CACGCGGGTCATGGTGGG-3’ (nucleotides:
51044-51296). The primers were designed to be complementary to
the splice junction. Fluorescence labelled nucleotide CyTM3-dUTP
(Amersham Biosciences, Little Chalfont Buckinghamshire, UK) was
used in order to identify the amplified product. hCGβ  mRNA dis-
tribution was analysed using Carl Zeiss LSM 510 confocal micro-
scope.
Computer generation of pseudocolours. The semi-quantitative
analysis of hCGβ  expression was based on computer image analysis.
Images generated in .lsm true colour file format from Zeiss LSM
image Browser Version 3,1,0,99 for Carl Zeiss Laser Scanning
System LSM 510 (Carl Zeiss GmbH) were exported to Microsoft®
Windows
® Bitmap File Format and saved. Using Adobe Photoshop
®
5.5 CEEA (Adobe Systems Inc.1989-1999), colour mode of the
images was changed to greyscale format (8 bit per channel; 256 grey
levels) and stored as Microsoft Windows® 8 Bitmap File Format.
Then, using the Scion Image® (Release beta 4.0.2) for Windows
software (Scion Corporation
© 2000), the greyscale was transformed
into 32 colour table mode and stored as pseudocolour images.
Results 
The results of the in situ RT-PCR (ISRT-PCR) study
performed on paraffin sections of tumour tissue demon-
strated the presence mRNA for beta subunit of human
chorionic gonadotropin in all cases, both in placenta
(data not shown) and in cancerous tissue. The distribu-
tion of hCGβ  mRNA in ovarian carcinoma was hete-
rogeneous: not all cells of the studied tissue revealed the
presence of the transcripts. The cells containing hCGβ
mRNA were usually organized in clusters characterized
by uniform and homogenous cytoplasmic staining.
Computer analysis and the use of pseudocolour scale
showed a clear difference in fluorescence intensity
among individual cancer cells. The intensity of ISRT-
PCR products corresponding with expression level of
hCGβ  demonstrated that its production by individual
cancer cells is different (Figs. 1, 2). The fluorescence
intensity measured after transformation into greyscale
reached even maximal level for some cancer cells,
whereas the other cells showed only weak or none
fluorescence (Figs. A, B). In the control tissue from the
same surgically removed material lacking the cancerous
changes, the hCGβ  mRNA was not detected (data not
shown). 
Discussion
The present study was undertaken to determine the
expression and distribution of hCGβ  mRNA in nontro-
phoblastic gynecological cancers. The study was based
Fig. 1. The results of ISRT-PCR in
ovarian cancer tissue. The cells con-
taining hCG gene products are visible
as bright spots. Fig. 2. The same image
after transformation to pseudocolours.
The cells containing hCG gene pro-
ducts are visible as yellow to red spots
in cancer tissue. The weakly fluores-
cent green cells do not express hCG. A,
B. The plots of the fluorescence intens-
ity of the cells measured along lines A
and B, respectively, shown in Fig. 2.
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tion of the signal, thus is more sensitive that in situ
hybridization [2, 13, 18, 24]. The findings of our re-
search indicate that mRNA of hCGβ  gene is present in
ovarian carcinoma tissue. This is, to our knowledge,
the first report, which directly revealed the production
and distribution of hCGβ  in ovarian tumors. At the
same time we demonstrated that noncancerous tissue
of the same women’s genital tract did not demonstrate
the expression of the gene. Thus, the present study
shows that expression of hCGβ  is characteristic feature
of the tumor tissue but its role in tumorogenesis is
unknown. 
The result of our study as well as other reports
demonstrated that besides placenta and malignant tro-
phoblastic diseases, a variety of tumors of different
origin secrete hCG and especially its β -subunit [3, 11,
20]. Recently, hCGβ -related low molecular weight ma-
terial has been demonstrated in the urine of pregnant
women and patients with trophoblastic and nontropho-
blastic tumors [14, 17, 21]. This material was termed
hCGβ -CF because it retains the hCGβ  core conforma-
tion determinant recognized by hCGβ  core antiserum
but lacks the carboxy-terminal portion of hCGβ  [1].
Currently, β -CF is receiving attention as a potential
tumor marker since elevated levels of β -CF were fre-
quently found in the urine of patients with nontropho-
blastic tumors even if immunoreactive hCGβ  could not
be detected in the serum [6, 19, 26]. The study performed
by Higashida et al. demonstrated the production of im-
munoreactive human chorionic gonadotropin beta-sub-
unit in case of one patient with ovarian malignant mixed
mesodermal tumor [10]. 
Our study based on ISRT-PCR technique showed
the distribution of cancer cells expressing the hCGβ  in
ovarian tumors. The positively stained cells were pres-
ent in all studied cancer tissue samples, however, in
some cases only single cells expressing hCGβ  were
observed. The tissue lacking the cancerous changes did
not show the presence of hCGβ  mRNA. Computer ana-
lysis and use of pseudocolour scale showed the dif-
ference in fluorescence intensity among individual
cancer cells of the analysed tissue. The intensity of
ISRT-PCR product fluorescence corresponding with the
expression level of hCGβ  showed that its production by
individual cells is different. Further investigations
should allow to determine the type of cancer cells ex-
pressing hCGβ  and to find out whether and when the
cells posses the ability to produce hCGβ  in preneoplastic
lesions. 
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